CuResponse

What CuResponse does

Curesponse (CURESPONSE Ltd.) is a privately-held, commercial-stage precision oncology company headquartered in Rehovot, Israel, with a secondary accredited laboratory in Sutton, UK. The company has developed the cResponse™ platform, a combined genomic-functional drug prioritization assay that integrates rapid next-generation sequencing (58 genes, over 1,000 hotspots) with functional ex vivo testing on living tumor tissue preserved in its native three-dimensional microenvironment. From a single biopsy, the platform evaluates drug response across chemotherapy, targeted biologics, and immunotherapy modalities and returns a cScore (0-100) ranking within approximately two weeks. The technology originated from research by Scientific Founder Dr. Ravid Straussman at the Weizmann Institute of Science, and the platform reports 96.5% sensitivity, 90% specificity across solid cancer types, and over 90% accuracy in breast cancer drug response prediction. The platform is CE-marked, ISO 15189-accredited under both ISRAC (Israel) and UKAS (UK), and is protected by a 2025 European Patent covering the discovery of a novel MEK-Src inhibitor combination in colorectal cancer.\n\nCuresponse operates two revenue streams: clinical diagnostic testing sold on a usage basis to oncologists and cancer patients (reimbursed in Israel by private payers including Migdal Insurance), and pharmaceutical partnership services that provide companion diagnostics, clinical trial patient selection, drug discovery, and mechanism-of-action studies to pharma developers. The go-to-market combines enterprise field sales targeting oncologists and hospitals directly with an exclusive distribution agreement signed with EDX Medical Group plc in June 2024 covering the UK, Sweden, Finland, Norway, and Denmark. Clinical collaborations are in place with leading medical centers including Sheba, Tel Aviv Sourasky (Ichilov), Rambam, and Imperial College London.\n\nThe company is led by Co-Founder & CEO Guy Neev and Co-Founder & CTO Dr. Seth Salpeter, with Scientific Founder Dr. Ravid Straussman anchoring the science. The technology is not yet approved by US Federal law for clinical use; selection into Startup Nation Central's February 2025 Israel Health-Tech Roadshow to the US indicates early US market development. Ownership is described as founder-led with no disclosed venture capital or private equity backing in the available materials.

Name

CuResponse

Legal name

CURESPONSE Ltd.

Website

https://curesponse.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Curesponse (CURESPONSE Ltd.) is an Israel-based precision oncology company offering the cResponse™ platform, which combines genomic sequencing with functional ex vivo drug testing on living tumor tissue to prioritize cancer therapies for oncologists, patients, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

Keywords

• Precision oncology testing
• Functional drug screening
• Tumor microenvironment analysis
• Companion diagnostics
• Cancer treatment prediction

Headquarters

HQ city

Tel Aviv-yafo

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Diagnostic Testing: Curesponse provides the cResponse test to oncologists and cancer patients, generating revenue through laboratory service fees. The test is reimbursed by private payers in Israel and is available through insurance coverage (Migdal insurance company).
2. Pharmaceutical Partnership Services: Provides companion diagnostics and drug development services to pharmaceutical companies, including patient selection for clinical trials, drug discovery, and mechanism-of-action studies. Used to accelerate drug development and identify new indications.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

cResponse is a genomic-functional drug prioritization platform that combines rapid next-generation sequencing (58 genes, >1000 hotspots) with functional ex vivo testing on living tumor tissue, preserving the tumor microenvironment during assessment. From a single biopsy, the platform evaluates chemotherapy, targeted biologics, and immunotherapy responses and delivers personalized treatment recommendations within 2 weeks. An integrated AI-driven scoring algorithm (cScore) ranks candidate therapies for the treating oncologist.

Product overview

Curesponse offers a single unified product: the cResponse™ platform, a combined genomic-functional precision medicine assay. The platform integrates rapid next-generation sequencing (58 genes, >1000 hotspots) with functional ex vivo testing on living tumor tissue maintained in its native microenvironment. It is the only assay of its kind that combines these two approaches to enable drug response assessment and prioritization across chemotherapy, targeted biologics, and immunotherapy modalities from a single biopsy sample, delivering results within 2 weeks.

Differentiator

Problem solved

Functional benefit

Brands

• cResponse™: Genomic-functional drug prioritization platform that predicts treatment response by testing therapies directly on patient tumor samples while preserving the tumor microenvironment.

Products and services

• cResponse™ Genomic-Functional Drug Prioritization Test Clinical diagnostic service that combines rapid 58-gene NGS (>1000 hotspots) with functional ex vivo drug screening on a single patient biopsy, preserving tumor microenvironment, and uses an AI cScore algorithm to prioritize chemotherapy, targeted biologic, and immunotherapy options for the treating oncologist within 2 weeks; CE marked and delivered from an ISO 15189-accredited laboratory.
• Pharmaceutical Partnership & Companion Diagnostics Services B2B service for biopharma sponsors covering companion diagnostic co-development and functional drug development using the same genomic-functional platform that preserves tumor microenvironment; supports CE-marked, ISO 15189-accredited assay-grade claims.

Quantifiable outcome

• 96.5% sensitivity and 90% specificity in predicting patient responses across solid cancer types
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Startup Nation CentralminorGTM or Marketing Partner · 6 February 2025Selected as one of 16 startups to represent Israeli health-tech excellence in the Israel Health-Tech Roadshow to the U.S., participating in meetings with healthcare providers, payers, and regulators in New York City, Chicago, and Philadelphia.
• EDX Medical Group plccoreChannel Partner/ Reseller/ Distributor · 26 June 2024Exclusive distribution agreement for marketing the cResponse cancer assay in the UK, Sweden, Finland, Norway, and Denmark. EDX Medical is a company developing digital diagnostic products supporting personalized cancer treatment.
• Imperial College LondoncoreStrategic or Co-development PartnerAcademic collaboration for clinical research and validation of the cResponse platform. Dr. Jonathan Krell served as study Principal Investigator for UK multi-center clinical study presented at AACR.
• Sheba Medical CentercoreStrategic or Co-development PartnerLeading Israeli medical center collaborating on clinical research. Dr. Raanan Berger (Head, Institute of Oncology) and Dr. Talia Golan (Head, Sheba Pancreatic Cancer Center) serve on Curesponse's Medical & Scientific Advisory Board.
• Tel Aviv Sourasky Medical Center (Ichilov Hospital)coreStrategic or Co-development PartnerMajor Israeli medical center collaborating on clinical research and technology development for precision oncology.
• Rambam HospitalcoreStrategic or Co-development PartnerLeading Israeli hospital collaborating on clinical research and validation of the cResponse platform.
• Migdal Insurance CompanycoreOthersMajor Israeli health insurance provider that covers the cResponse test for policyholders, enabling patient access to precision oncology testing.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company whose Guardant360 and Reveal tests compete for the same oncologist decision point on treatment selection that Curesponse targets via a tissue-based functional assay.
• Foundation Medicine: Foundation Medicine is the leading comprehensive genomic profiling provider in oncology (now part of Roche) and competes for the same oncologist ordering decision as Curesponse, albeit with a purely genomic rather than combined genomic+functional approach.
• Natera: Natera offers Signatera and other molecular oncology tests for therapy selection and monitoring — competing for the same oncologist ordering slot while operating at a far broader scale than Curesponse's tumor-tissue-based test.
• Tempus Labs: Tempus combines next-generation sequencing with an AI/data platform for oncology decision support and pharma services — matching Curesponse's blend of sequencing + analytical insights + pharma services revenue streams.
• Caris Life Sciences: Caris offers MI Profile molecular profiling and Caris Assure blood-based monitoring alongside AI-driven analytics for oncology — comparable as a multi-modality precision oncology platform serving the same oncologist and pharma-services customer base.

Direct peers

• Champions Oncology: Champions Oncology offers functional precision oncology testing via its Lumin/PDX platform to predict drug response from patient tumor samples — directly comparable to Curesponse's cResponse ex vivo functional assay in offering, modality coverage, and oncologist customer base.
• SEngine Precision Medicine: SEngine runs a functional precision oncology service (3D-PLS) that tests drugs on patient-derived tumor organoids/microspheres to guide oncology treatment selection — overlapping with Curesponse's living-tumor functional prioritization platform serving the same oncology precision-medicine use case.
• Notable Labs: Notable Labs operates a functional precision oncology platform that screens patient tumor samples against candidate therapies to prioritize treatment — directly comparable to Curesponse's approach of ranking drugs by ex vivo efficacy for individual cancer patients.
• Certis Oncology (Concensus Medicine): Certis Oncology provides functional oncology testing using patient-derived tumor models plus AI to predict drug response — matching Curesponse's combined living-tumor functional assay + AI cScore methodology for personalized cancer treatment selection.

Emerging players

• Xilis: Xilis develops MicroOrganoSphere functional precision oncology technology from patient biopsies — overlapping with cResponse as an emerging functional ex vivo testing platform, though focused on micro-organoid droplets rather than intact-tissue microenvironment preservation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@curesponse/featured
• LinkedInlinkedin.com/company/curesponse

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CuResponse